Predictors of mortality and early detection strategies for hepatopulmonary syndrome in liver transplant patients
Introduction: Hepatopulmonary syndrome (HPS) is a serious, progressive disease. Its pathophysiology resides in a hypoxic intrapulmonary shunt and severe clinical deterioration. Liver transplantation (LT) is the only effective treatment in appropriately selected patients.
Objective: To acknowledge the importance of early diagnosis of HPS.
Patients and methods: Observational, descriptive, retrospective trial including 8 patients with HPS that received LT between April 2006 and August 2014. The clinical data prior to transplantation and follow-up after the procedure were reviewed.
A multivariate analysis (stepwise forward logistic regression analysis) was used to identify the variable that could potentially increase the risk of death.
Results: Of the 8 patients, death could only be significantly predicted based on the pre-LT arterial blood partial oxygen pressure (PaO2) (p = 0.002).
The average pre-LT PaO2 of the patients that died was 51.5 ±2.49 SD, with a statistically significant difference (p = 0.002).
None of the variables was statistically significant for HPS reversibility.
The survival rate of patients diagnosed with HPS following the LT was 62.5%.
ConcIusions: The level of pre-LT hypoxemia is an important predictor for immediate postoperative mortality. Early detection of the condition is critical to reduce the post LT morbidity and mortality so that the indication for transplant is made at the right time, regardless of the stage of liver disease. The most efficient clinical strategy could be the use of appropriate early detection protocols for HPS through screening of hypoxemia in patients with portal hypertension.
2. Aldenkortt F, Aldenkortt M, Caviezel L, Waeber JL, Weber A, Schiffer E. Portopulmonary hypertension and hepatopulmonary syndrome. World J Gastroenterol. 2014;20:8072-81.
3. Khan AN, Al-Jahdali H, Abdullah K, Irion KL, Sabih Q, Gouda A. Pulmonary vascular complications of cronic liver disease: pathophysiology, imaging, and treatment. Ann thorac Med. 2011;6:57-65.
4. Brugts JJ, Michels M, Den Uil CA. A Cardiac diagnosis by contrast echocardiography. Heart. 2014;100:657-61.
5. Rodriguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome - a liver-induced lung vascular disorder. N Engl J Med. 2008;358:2378-87.
6. Tanikella R, Fallon MB. Hepatopulmonary síndrome and liver transplantation: who, when, and where? Hepatology. 2013;57:2097-9.
7. Pascasio JM, Grilo I, López-Pardo FJ, Ortega-Ruíz F, Tirado JL, Sousa JM, et al. Prevalence anda severity oh hepatopulmonary síndrome and its influence on survival in cirrhotic patients evaluated for liver transplantation. Am J Transplant. 2014;14:1391-9.
8. Valenti A, Caimi G. Physiopathological, clinical and therapeutic aspects of hepatopulmonary syndrome. Clin Ter. 2010;161:123-8.
9. Suceveanu AI, Mazilu L, Tomescu D, Ciufu N, Parepa IR, Suceveanu AP. Screening of hepatopulmonary síndrome (HPS) with CEUS and pulse-oximetry in liver cirrhosis patients eligible for liver transplantation. Chirurgia (Bucur). 2013;108:684-8.
10. Krowka MJ, Wiesner RH, Heimbach JK. Pulmonary contraindications, indications and MELD exceptions for liver transplantation: a contemporary review and look forward. J Hepatol. 2013;59:367-74.
11. Nacif LS, Andraus W, Sartori K, Benites CM, Santos VR, Rocha-Filho JA, et al. Hypoxia among patients on the liver-transplant waiting list. Arq Bras Cir Dig. 2014;27:56-8.
12. Koch DG, Fallon MB. Hepatopulmonary syndrome. Clin Liver Dis. 2014;18:407-20.
13. Casey S, Schellenman A, Angus P. Recurrence of hepatopulmonary syndrome post-orthotopic liver transplantation in a patient with noncirrhotic portal hypertension. Hepaotology. 2013;58:2205-6.
14. Taneja S, Manavwadhawan, Gupta S, Neeravgoyal, Ramaswamy KV, Chaudhary A. Congenital hepatic fibrosis with extra-hepatic porto-systemic shunt and hepatopulmonary syndrome successfully managed with living related liver transplantation Trop Gastroenterol. 2014;35:116-8.
15. Abrams GA, Sanders MK, Fallon MB. Utility of pulse oximetry in the detection of arterial hipoxemia in liver transplant candidates. Liver Transpl. 2002;8:391-6.
16. Roberts ND, Arguedas MR, Fallon MB. Cost-effectiveness of screening for hepatopulmonar syndrome in liver transplant candidates. Liver Transpl. 2007;13:206-14.
17. Zhang J, Fallon MB. Hepatopulmonary syndrome: update on pathogenesis and clinical features. Nat Rev Gastroenterol Hepatol. 2012;9:539-49.
18. Fauconnet P, Klopfenstein CE, Schiffer E. Hepatopulmonary syndrome: the anaesthetic considerations. Eur J Anaesthesiol. 2013;30:721-30.
19. Asthana S, Maguire C, Lou L, Meier M, Bain V, Townsend DR, et al. Successful resolution of severe hepatopulmonary syndrome following liver transplantation. Traspl Int. 2010;23:432-5.
20. Porres-Aguilar M, Gallegos-Orozco JF. Hepatopulmonary syndorme: is it time to redefine the MELD exception score for better organ allocation and outcomes? Ann Hepatol. 2014;13:468-70.
21. Gupta S, Castel H, Rao RV, Picard M, Lilly L, Faughnan ME, et al. Improved survival after liver transplantation in patients with hepatopulmonary syndrome. Am J Transplant. 2010;10:354-63.
22. Nayyar D, Man HS, Granton J, Gupta S. Defining and characterizing severe hipoxemia after liver transplantation in hepatopulmonary síndrome. Liver Transpl. 2014;20: 182-90.
23. Horvatits T, Fuhrmann V. Therapeutic options in pulmonary hepatic vascular diseases. Exp Rev Clin Pharmacol. 2014;7:31-42.
Copyright (c) 2016 Sociedad Colombiana de Anestesiología y Reanimación. S.C.A.R.E
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.